Skip to main content
SpringerLink
Log in

Clinical Implications of Measuring Quality-of-Life in Early Stage Prostate Cancer

  • Chapter
  • First Online:
Book cover Management of Prostate Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 1455 Accesses

Abstract

Prostate cancer is a unique malignancy: it is the most prevalent cancer in men (CA Cancer J Clin 60(5):277–300, 2010), and yet most cases have a relatively indolent course when compared to other malignancies, with most men dying from other causes before becoming symptomatic (Am J Epidemiol 148:775–785, 1998). Because an informed medical decision can only be made with a thorough understanding of the risks and benefits of each management option, an increasingly bright spotlight has been placed on the effects of prostate cancer treatment on patients’ health-related quality-of-life (HRQOL), as every treatment modality for early stage prostate cancer portends distinct HRQOL consequences (JAMA 273:129–135, 1995; J Natl Cancer Inst 92:1582–1592, 2000; N Engl J Med 358:1250–1261, 2008). Prostatectomy carries an increased risk of urinary incontinence, external radiotherapy and brachytherapy can cause bowel toxicity and urinary obstruction or irritation, hormonal therapy affects vitality, and each of these treatments can result in deterioration of sexual function. While the presence of these adverse outcomes can sometimes be self-evident during the course of routine clinical care, objectively quantifying such outcomes can be challenging.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. Erratum in: CA Cancer J Clin. 2011;61(2):133–4.

    Google Scholar 

  2. Etzioni R, Cha R, Feuer EJ, et al. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol. 1998;148:775–85.

    Article  PubMed  CAS  Google Scholar 

  3. Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273(2):129–35.

    Article  PubMed  CAS  Google Scholar 

  4. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000;92(19):1582–92.

    Article  PubMed  CAS  Google Scholar 

  5. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12): 1250–61.

    Article  PubMed  CAS  Google Scholar 

  6. Lubeck DP, Litwin MS, Henning JM, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1996; 48:773.

    Article  PubMed  CAS  Google Scholar 

  7. Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol. 2009;27(24):3916–22.

    Article  PubMed  Google Scholar 

  8. Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011;306(11):1205–14.

    Article  PubMed  CAS  Google Scholar 

  9. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.

    Article  PubMed  Google Scholar 

  10. Quinlan DM, et al. Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol. 1991;145(5):998–1002.

    PubMed  CAS  Google Scholar 

  11. Catalona WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol. 1999;162(2):433–8.

    Article  PubMed  CAS  Google Scholar 

  12. Fowler FJ, Barry Jr MJ, Lu-Yao G, et al. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988–1990 (updated June 1993). Urology. 1993;42(6):622–9.

    Article  PubMed  Google Scholar 

  13. Litwin MS, Lubeck DP, Henning JM, Carroll PR. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol. 1998;159(6):1988–92.

    Article  PubMed  CAS  Google Scholar 

  14. Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. 2nd ed. Oxford: Oxford University Press; 1995.

    Google Scholar 

  15. Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905.

    Article  PubMed  CAS  Google Scholar 

  16. Szymanski KM, Wei JT, Dunn RL, et al. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76(5): 1245–50.

    Article  PubMed  Google Scholar 

  17. Gore JL, Gollapudi K, Bergman J, Kwan L, Krupski TL, Litwin MS. Correlates of bother following treatment for clinically localized prostate cancer. J Urol. 2010;184(4):1309–15.

    Article  PubMed  Google Scholar 

  18. Wyrwich KW, Wolinsky FD. Identifying meaningful intra-individual change standards for health-related quality of life measures. J Eval Clin Pract. 2000;6(1): 39–49.

    Article  PubMed  CAS  Google Scholar 

  19. Hollenbeck BK, Dunn RL, Wei JT, Montie JE, Sanda MG. Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument. J Urol. 2003;169(4):1453–7.

    Article  PubMed  Google Scholar 

  20. Barry MJ, Fowler Jr FJ, O’Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549–57.

    PubMed  CAS  Google Scholar 

  21. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;335(8):533–9.

    Article  PubMed  CAS  Google Scholar 

  22. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338(9):557–63.

    Article  PubMed  CAS  Google Scholar 

  23. McConnell JD, Roehrborn CG, Bautista OM, et al., and the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98.

    Google Scholar 

  24. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–30.

    Article  PubMed  CAS  Google Scholar 

  25. Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11(6):319–26.

    Article  PubMed  CAS  Google Scholar 

  26. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36(7): 1002–12.

    Article  PubMed  CAS  Google Scholar 

  27. Downs TM, Sadetsky N, Pasta DJ, Grossfeld GD, Kane CJ, Mehta SS, et al. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer—data from CaPSURE. J Urol. 2003;170(5):1822–7.

    Article  PubMed  Google Scholar 

  28. Chang P, Szymanski KM, Dunn RL, et al. Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): development and validation of a practical health-related quality of life instrument for use in the routine clinical care of prostate cancer patients. J Urol. 2011;186(3):856–72.

    Article  Google Scholar 

  29. Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50(6):920–8.

    Article  PubMed  CAS  Google Scholar 

  30. Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care. 2001;39(10):1118–30.

    Article  PubMed  CAS  Google Scholar 

  31. Borghede G, Sullivan M. Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30. Qual Life Res. 1996;5(2):212–22.

    Article  PubMed  CAS  Google Scholar 

  32. Giesler RB, Miles BJ, Cowen ME, Kattan MW. Assessing quality of life in men with clinically localized prostate cancer: development of a new instrument for use in multiple settings. Qual Life Res. 2000;9(6): 645–65.

    Article  PubMed  CAS  Google Scholar 

  33. Roth AJ, Rosenfeld B, Kornblith AB, et al. The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with prostate cancer. Cancer. 2003;97(11):2910–8.

    Article  PubMed  Google Scholar 

  34. Namiki S, Takegami M, Kakehi Y, et al. Analysis linking UCLA PCI with Expanded Prostate Cancer Index Composite: an evaluation of health related quality of life in Japanese men with localized prostate cancer. J Urol. 2007;178(2):473–7; discussion 477.

    Google Scholar 

  35. Schroeck FR, Donatucci CF, Smathers EC, et al. Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer. 2008;113(10):2687–94.

    Article  PubMed  Google Scholar 

  36. Levinson AW, Ward NT, Sanda MG, et al. Comparison of validated instruments measuring sexual function in men. Urology. 2010;76(2):380–6.

    Article  PubMed  Google Scholar 

  37. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347:790–6.

    Article  PubMed  Google Scholar 

  38. Potosky AL, Harlan LC, Stanford JL, et al. Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 1999;91(20):1719–24.

    Article  PubMed  CAS  Google Scholar 

  39. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000;283(3):354–60.

    Article  PubMed  CAS  Google Scholar 

  40. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96(18):1358–67.

    Article  PubMed  Google Scholar 

  41. Penson DF, McLerran D, Feng Z, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol. 2005;173(5):1701–5.

    Article  PubMed  Google Scholar 

  42. Litwin MS, Pasta DJ, Yu J, et al. Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2000;164(6): 1973–7.

    Article  PubMed  CAS  Google Scholar 

  43. Hu JC, Elkin EP, Pasta DJ, et al. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol. 2004;171(2 Pt 1):703–7; discussion 707–8.

    Google Scholar 

  44. Arredondo SA, Downs TM, Lubeck DP, et al. Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol. 2008;179(5 Suppl):S14–8.

    Article  PubMed  Google Scholar 

  45. Arredondo SA, Elkin EP, Marr PL, et al.; CaPSURE Investigators. Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: data from CaPSURE. Urology. 2006;67(3): 559–65.

    Google Scholar 

  46. Shah NL, Dunn RL, Greenfield TK, et al. Development and validation of a novel instrument to measure patient satisfaction in multiple dimensions of urological cancer care quality. J Urol. 2003;169(Suppl):11, abstract.

    Google Scholar 

  47. Smith DP, King MT, Egger S, et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ. 2009;339: b4817.

    Article  PubMed  Google Scholar 

  48. Ferrer M Suárez JF, Guedea F; Multicentric Spanish Group of Clinically Localized Prostate Cancer. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(2):421–32.

    Google Scholar 

  49. Pardo Y, Guedea F, Aguiló F, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol. 2010;28:4687–96.

    Article  PubMed  Google Scholar 

  50. Madalinska JB, Essink-Bot ML, de Koning HJ, et al. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol. 2001;19(6):1619–28.

    PubMed  CAS  Google Scholar 

  51. Korfage IJ, Essink-Bot ML, Borsboom GJ, et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer. 2005;116(2):291–6.

    Article  PubMed  CAS  Google Scholar 

  52. Sanda MG, Kaplan ID. A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment. JAMA. 2009;301(20):2141–51.

    Article  PubMed  CAS  Google Scholar 

  53. Krupski TL, Saigal CS, Litwin MS. Variation in continence and potency by definition. J Urol. 2003;170: 1291–4.

    Article  PubMed  Google Scholar 

  54. Wei JT, Montie JE. Comparison of patients’ and physicians’ rating of urinary incontinence following radical prostatectomy. Semin Urol Oncol. 2000;18:76.

    PubMed  CAS  Google Scholar 

  55. Huang GJ, Sadetsky N, Penson DF. Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol. 2010;183(6): 2206–12.

    Article  PubMed  Google Scholar 

  56. Konety BR, Sadetsky N, Carroll PR; CaPSURE Investigators. Recovery of urinary continence following radical prostatectomy: the impact of prostate volume—analysis of data from the CaPSURE Database. J Urol. 2007;177(4):1423–5; discussion 1425–6.

    Google Scholar 

  57. Lepor H, Kaci L. The impact of open radical retropubic prostatectomy on continence and lower urinary tract symptoms: a prospective assessment using ­validated self-administered outcome instruments. J Urol. 2004;171(3):1216–9.

    Article  PubMed  Google Scholar 

  58. Slova D, Lepor H. The short-term and long-term effects of radical prostatectomy on lower urinary tract symptoms. J Urol. 2007;178(6):2397–400; discussion 2400–1.

    Google Scholar 

  59. Masters JG, Rice ML. Improvement in urinary symptoms after radical prostatectomy: a prospective evaluation of flow rates and symptom score. BJU Int. 2003;91:795–7.

    Article  PubMed  CAS  Google Scholar 

  60. Mulhall JP. Defining and reporting erectile function outcomes after radical prostatectomy: challenges and misconceptions. J Urol. 2009;181(2):462–71.

    Article  PubMed  Google Scholar 

  61. Bennett NE Jr, Stasi J, Eastham JA, et al. The chronology of erectile function loss after radical prostatectomy. J Urol Suppl. 2007;177:285, abstract 856.

    Google Scholar 

  62. Rabbani F, Stapleton AM, Kattan MW, et al. Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000;164:1929.

    Article  PubMed  CAS  Google Scholar 

  63. Ayyathurai R, Manoharan M, Nieder AM, et al. Factors affecting erectile function after radical retropubic prostatectomy: results from 1620 consecutive patients. BJU Int. 2008;101(7):833–6.

    Article  PubMed  Google Scholar 

  64. Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002;346:1138.

    Article  PubMed  Google Scholar 

  65. Bianco FJ Jr, Kattan MW, Eastham JA, et al. Role of surgeon and surgeon volume in erectile function recovery after radical prostatectomy. J Urol. 2006;175(Suppl):70, abstract 212.

    Google Scholar 

  66. Gore JL, Kwan L, Lee SP, et al. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst. 2009;101(12):888–92.

    Article  PubMed  Google Scholar 

  67. Pinkawa M, Fischedick K, Asadpour B, et al. Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):83–9.

    Article  PubMed  Google Scholar 

  68. Christie D, Denham J, Steigler A, et al. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiother Oncol. 2005;77(2):117–25.

    Article  PubMed  Google Scholar 

  69. Beard CJ, Propert KJ, Rieker PP, et al. Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study. J Clin Oncol. 1997;15(1):223–9.

    PubMed  CAS  Google Scholar 

  70. D’Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821–7.

    Article  PubMed  Google Scholar 

  71. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295.

    Article  PubMed  CAS  Google Scholar 

  72. Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243.

    Article  PubMed  CAS  Google Scholar 

  73. Litwin MS, Sadetsky N, Pasta DJ, Lubeck DP. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE. J Urol. 2004;172(2):515–9.

    Article  PubMed  Google Scholar 

  74. Pollack A, Zagars GK. External beam radiotherapy dose–response of prostate cancer. Int J Radiat Oncol Biol Phys. 1997;39:1011.

    Article  PubMed  CAS  Google Scholar 

  75. Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 1999;85(11):2460–8.

    Article  PubMed  CAS  Google Scholar 

  76. Smit WG, Helle PA, van Putten WL, et al. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys. 1990;18:23.

    Article  PubMed  CAS  Google Scholar 

  77. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.

    Article  PubMed  CAS  Google Scholar 

  78. Syndikus I, Morgan RC, Sydes MR, et al.; MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Radiat Oncol Biol Phys. 2010;77(3):773–83.

    Google Scholar 

  79. McElveen TL, Waterman FM, Kim H, Dicker AP. Factors predicting for urinary incontinence after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2004;59(5):1395–404.

    Article  PubMed  Google Scholar 

  80. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003;21(21):3979–86.

    Article  PubMed  Google Scholar 

  81. Gage AA. History of cryosurgery. Semin Surg Oncol. 1998;14:99–109.

    Article  PubMed  CAS  Google Scholar 

  82. Babaian RJ, Bahn D, Baust JG, et al. Best practice policy statement on: cryosurgery for the treatment of localized prostate cancer. American Urological Association Education and Research Inc; 2008. p. 1–51. http://www.auanet.org/content/media/cryosurgery08.pdf

  83. Jones JS, Rewcastle JC, Donnelly BJ, et al. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol. 2008;180(2): 554–8.

    Article  PubMed  Google Scholar 

  84. Robinson JW, Donnelly BJ, Siever JE, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer. 2009;115(20): 4695–704.

    Article  PubMed  Google Scholar 

  85. Warmuth M, Johansson T, Mad P. Systematic review of the efficacy and safety of high-intensity focused ultrasound for the primary and salvage treatment of prostate cancer. Eur Urol. 2010;58(6):803–15.

    Article  PubMed  Google Scholar 

  86. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948–54.

    Article  PubMed  CAS  Google Scholar 

  87. Klotz L. Expectant management with selective delayed intervention for favorable risk prostate cancer. Urol Oncol. 2002;7(5):175–9.

    Article  PubMed  Google Scholar 

  88. Hegarty J, Beirne PV, Walsh E, et al. Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database Syst Rev. 2010;11:CD006590.

    Google Scholar 

  89. Johansson E, Bill-Axelson A, Holmberg L, et al.; Scandinavian Prostate Cancer Group Study No 4. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol. 2009;55(2): 422–30.

    Google Scholar 

  90. Parker C. Active surveillance of early prostate cancer: rationale, initial results and future developments. Prostate Cancer Prostatic Dis. 2004;7(3):184–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Beth Israel Deaconess Medical Center, Harvard Program in Urology, 330 Brookline Avenue, Rabb 440, Boston, MA, 02215, USA

    Peter Chang, Mehrdad Alemozaffar & Martin G. Sanda

Authors
  1. Peter Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehrdad Alemozaffar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin G. Sanda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin G. Sanda .

Editor information

Editors and Affiliations

  1. , Glickman Urological and Kidney, Cleveland Clinic, 9500 Euclid Ave, Cleveland, 44195, Ohio, USA

    Eric A. Klein

  2. Cleveland Clinic, Cleveland Clinic Lerner College of Medic, Department of Regional Urology, at Case Western Reserve, Cleveland, 44195, Ohio, USA

    J. Stephen Jones

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Chang, P., Alemozaffar, M., Sanda, M.G. (2012). Clinical Implications of Measuring Quality-of-Life in Early Stage Prostate Cancer. In: Klein, E., Jones, J. (eds) Management of Prostate Cancer. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-259-9_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-259-9_19

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-258-2

  • Online ISBN: 978-1-60761-259-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation